Company’s two new antibiotic drugs may reach global markets in 30-36 months, says Wockhardt

Wockhardt is in focus after the Indian Drug Regulator -Drug Controller General of India (DCGI) approved two of the company's new antibiotics.

Throwing more light on the above approval Habil F Khorakiwala Founder, Chairman and Group CEO of the company said, “We have two molecules WCK 5222 and WCk 4282 that will be entering global markets. Currently, they are entering phase III clinical trials, which could take about 18-24 months. Post that within six months to a year we should receive the approval." The overall timeline for them to be available in global market is about two and half to three years, he added.

Talking about debt plan he said, “We are refinancing the old debts and building up a liquidity from growth point of view. We would be taking certain effective measure to make sure that we have enough funding available for our own future growth." We have done all our payment commitments of 2019, he added.